Quick facts
- Class
- Mitochondrial-derived peptide (16 aa)
- Studied for
- Insulin sensitivity, metabolism, aging
- Evidence level
- Preclinical (mostly animal/cell)
- Approval
- Not FDA-approved
- Drug class
- Mitochondrial-derived peptide (MDP)
- Development stage
- Preclinical research
- Approval status
- Not approved; research chemical
- Proposed role
- Exercise-mimetic / metabolic regulator
Key takeaways
- MOTS-c is a mitochondrial-derived peptide, encoded within mitochondrial DNA, that is studied as a regulator of metabolism.
- It is being investigated as an exercise-mimetic and metabolic peptide, with effects observed mainly in cell and animal models.
- Research is preclinical; it is not an approved drug and has not been established as safe or effective in humans.
- Proposed actions include influencing insulin sensitivity, energy homeostasis, and stress responses via pathways such as AMPK.
- It is sold as a research chemical, and human clinical evidence for marketed uses is lacking.
Overview
MOTS-c is a mitochondrial-derived peptide, meaning it is encoded within the small genome housed inside mitochondria rather than the main nuclear genome. It belongs to a class of short peptides that appear to act as signaling molecules, and it has attracted scientific interest as a potential regulator of metabolism and a so-called exercise mimetic.
Researchers have studied MOTS-c primarily in cell and animal models, where it has been linked to improved insulin sensitivity, enhanced metabolic flexibility, and responses that resemble some effects of physical exercise. These findings have made it a subject of curiosity in fields ranging from metabolic disease to aging biology.
It is essential to be clear about its status: MOTS-c is a research chemical at the preclinical stage. It is not an approved drug, has not been validated through robust human clinical trials, and any consumer-facing product containing it is operating well ahead of the established science.
How it works
MOTS-c is thought to act as a signal that links mitochondrial status to the rest of the cell and to whole-body metabolism. A central proposed mechanism involves activation of AMP-activated protein kinase, or AMPK, a cellular energy sensor that becomes active when energy is scarce and that promotes glucose uptake and fat oxidation.
Through this AMPK-related pathway, MOTS-c has been reported in laboratory settings to enhance the way cells take up and use glucose, supporting insulin sensitivity and metabolic adaptation. Some research also suggests it can translocate to the cell nucleus under metabolic stress and influence gene expression related to stress responses and metabolism.
These mechanisms are compelling but remain largely characterized in cellular and animal systems. The degree to which they operate meaningfully and safely in humans, and at what exposures, has not been established, so the mechanistic picture should be read as promising biology rather than proven human pharmacology.
Research & evidence
The evidence base for MOTS-c is dominated by preclinical work. In rodent studies, it has been associated with improved glucose handling, resistance to diet-induced metabolic dysfunction, and exercise-like benefits, and observational research has explored how natural MOTS-c levels relate to metabolic health and physical performance.
This animal and cellular research is genuinely interesting and has fueled hypotheses about applications in metabolic disease, insulin resistance, and aging. However, encouraging preclinical results routinely fail to reproduce in humans, and MOTS-c has not yet been validated through the large, controlled human trials that would be needed to support therapeutic claims.
As a result, statements that MOTS-c improves human metabolism, athletic performance, or longevity are not supported by adequate clinical evidence. The peptide remains an active research target whose human relevance is still being investigated rather than an established intervention.
Safety & legal status
Because MOTS-c has not undergone comprehensive human clinical testing, its safety profile in people is essentially unknown. There is little reliable information on appropriate exposure, long-term effects, or interactions, and this guide does not provide any administration guidance.
Material marketed as MOTS-c is typically sold as a research chemical, often explicitly labeled as not for human consumption. Such products are not manufactured to pharmaceutical standards, and purity, identity, and sterility can vary substantially between sources, adding risk that is independent of the molecule itself.
Legally, MOTS-c is not an approved medicine, and selling it for human use generally falls outside regulatory approval. Athletes should also be cautious, as metabolic and performance-modifying peptides can attract anti-doping attention. The responsible framing is that MOTS-c is an experimental compound suited to the laboratory, not to self-administration.
Frequently asked questions
What is MOTS-c?
MOTS-c is a small peptide encoded within mitochondrial DNA, classified as a mitochondrial-derived peptide. It has been studied for its potential role in regulating metabolism and energy balance.
Is MOTS-c proven to work in humans?
No. Most evidence comes from laboratory and animal studies, and it has not been established as safe or effective in humans through controlled clinical trials. It is best regarded as a research compound.
Why is MOTS-c called an exercise-mimetic?
In preclinical studies it appears to activate metabolic pathways, such as AMPK signaling, that overlap with some effects of physical exercise. This has led to interest in it as a potential exercise-mimetic, though this is not clinically validated.
Is MOTS-c approved or available as a medicine?
No. It is not approved by any major regulator and is sold as a research chemical. Such products are unregulated and not intended for human use.
What does mitochondrial-derived peptide mean?
It refers to small peptides whose codes lie within mitochondrial DNA rather than the cell nucleus. These peptides, including MOTS-c, are thought to act as signaling molecules influencing cellular metabolism.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. Peer-reviewed study
- Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016. Peer-reviewed study
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023. Peer-reviewed study
- Kong BS, Lee C, Cho YM. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes Metab J. 2023. Peer-reviewed study
- Yin Y, Li Y, Ma B, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Adv Sci (Weinh). 2024. Peer-reviewed study
- Yin Y, Pan Y, He J, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022. Peer-reviewed study